Nonmotor and extracerebellar features in Machado-Joseph disease: A review

Movement Disorders

Volumn 28, Issue 9, 2013, Pages 1200-1208

  Pedroso, José Luiz ^a   França, Marcondes C ^b   Braga Neto, Pedro ^a   D'Abreu, Anelyssa ^b   Saraiva Pereira, Maria Luiza ^c,d   Saute, Jonas A ^c,d   Teive, Hélio A ^e   Caramelli, Paulo ^f   Jardim, Laura Bannach ^c,d   Lopes Cendes, Iscia ^b   Barsottini, Orlando Graziani P ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Extracerebellar signs; Machado Joseph disease; Nonmotor symptoms; spinocerebellar ataxia type 3

Indexed keywords

ATAXIN 3;

COGNITIVE DEFECT; DYSAUTONOMIA; DYSTONIA; FATIGUE; HUMAN; MACHADO JOSEPH DISEASE; MEDLINE; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE CRAMP; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; NUTRITIONAL HEALTH; PAIN; PARKINSONISM; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SMELLING DISORDER; SPASTICITY; SYSTEMATIC REVIEW;

EXTRACEREBELLAR SIGNS; MACHADO-JOSEPH DISEASE; NONMOTOR SYMPTOMS; SPINOCEREBELLAR ATAXIA TYPE 3;

BRAIN; COGNITION DISORDERS; HUMANS; MACHADO-JOSEPH DISEASE; MENTAL DISORDERS; MOVEMENT DISORDERS; MUSCLE CRAMP; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; NUTRITION DISORDERS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; REPRESSOR PROTEINS; SLEEP DISORDERS;

EID: 84883559735     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25513     Document Type: Review

References (96)

1. Schos L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004;3:291-304.
2. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol 2001;58:899-904.
3. Nakano KK, Dawson DM, Spence A. Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology 1972;22:49-55.
4. Pedroso JL, Braga-Neto P, Radavany J, Barsottini OG. Machado-Joseph disease in Brazil: from the first descriptions to the emergence as the most common spinocerebellar ataxia. Arq Neuropsiquiatr 2012;70:630-632.
5. Igarashi S, Takiyama Y, Cancel G, et al. Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. Hum Mol Genet 1996;5:923-932.
6. D'Abreu A, Franca MC Jr, Paulson HL, Lopes-Cendes I. Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat Disord 2010;16:2-7.
7. Riess O, Rub U, Pastore A, Bauer P, Schols L. SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008;7:125-137.
8. D'Abreu A, Franca MC Jr, Yasuda CL, Campos BA, Lopes-Cendes I, Cendes F. Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study. J Neuroimaging 2012;22:285-291.
9. Grimaldi G, Manto M. Topography of cerebellar deficits in humans. Cerebellum 2011;11:336-351.
10. Paulson HL, Das SS, Crino PB, et al. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 1997;41:453-462.
11. Klockgether T, Skalej M, Wedekind D, et al. 1998. Autosomal dominant cerebellar ataxia type I, MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 1998;121:1687-1693.
12. Rub U, Brunt ER, Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 2008;21:111-116..
13. D'Abreu A, Franca MC Jr, Yasuda CL, Souza MS, Lopes-Cendes I, Cendes F. Thalamic volume and dystonia in Machado-Joseph disease. J Neuroimaging 2012;21:e91-e93.
14. D'Abreu A, Franca MC JR, Appenzeller S, Lopes-Cendes I, Cendes F. Axonal dysfunction in the deep white matter in Machado-Joseph disease. J Neuroimaging 2009;19:9-12.
15. Taniwaki T, Sakai T, Kobayashi T, et al. Positron emission tomography (PET) in Machado-Joseph disease. J Neurol Sci 1997;145:63-67.
16. Braga-Neto P, Felicio AC, Hoexter MQ, et al. Cognitive and olfactory deficits in Machado-Joseph disease: a dopamine transporter study. Parkinsonism Relat Disord 2012;18:854-858.
17. Schmidt T, Landwehrmeyer GB, Schmitt I, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 1998;8:669-679.
18. Rub U, Seidel K, Ozerden I. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res 2007;53:235-249.
19. Seidel K, den Dunnen WF, Schultz C, et al. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 2010;120:449-460.
20. Khan LA, Bauer PO, Miyazaki H, Lindenberg KS, Landwehrmeyer BG, Nukina N. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. J Neurochem 2006;98:576-587.
21. Chou AH, Yeh TH, Ouyang P, Chen YL, Chen SY, Wang HL. Polyglutamine expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis 2008;31:89-101.
22. Raggi A, Ferri R. Sleep disorders in neurodegenerative diseases. Eur J Neurol 2010;17:1326-1338.
23. D'Abreu A, Franca M Jr, Conz L, et al. Sleep symptoms and their clinical correlates in Machado-Joseph disease. Acta Neurol Scand 2009;119:277-280.
24. Pedroso JL, Braga-Neto P, Felicio AC, et al. Sleep disorders in cerebellar ataxias. Arq Neuropsiquiatr 2011;69:253-257.
25. Pedroso JL, Braga-Neto P, Felicio AC, et al. Sleep disorders in Machado-Joseph disease: frequency, discriminative thresholds, predictive values, and correlation with ataxia-related motor and non-motor features. Cerebellum 2011;10:291-295.
26. Pedroso JL, Bezerra ML, Braga-Neto P, et al. Is neuropathy involved with restless legs syndrome in Machado-Joseph disease? Eur Neurol 2011;66:200-203.
27. Pedroso JL, Bor-Seng-Shu E, Felicio AC, Braga-Neto P, Teixeira MJ, Barsottini OG. Transcranial sonography findings in spinocerebellar ataxia type 3 (Machado-Joseph disease): a cross-sectional study. Neurosci Lett 2011;504:98-101.
28. Pedroso JL, Bor-Seng-Shu E, Felicio AC, et al. Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. A preliminary observation. J Neurol Sci 2012;319:59-62.
29. Schols L, Haan J, Riess O, Amoiridis G, Przuntek H. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 1998;51:1603-1607.
30. Reimold M, Globas C, Gleichmann M, et al. Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. Mov Disord 2006;21:1667-1673.
31. Pedroso JL, Braga-Neto P, Felicio AC, et al. Sleep disorders in Machado-Joseph disease: a dopamine transporter imaging study. J Neurol Sci 2013;324:90-93.
32. Iranzo A, Munoz E, Santamaria J, Vilaseca I, Mila M, Tolosa E. REM sleep behavior disorder and vocal cord paralysis in Machado-Joseph disease. Mov Disord 2003;18:1179-1183.
33. D'Abreu A, Friedman J, Coskun J. Non-movement disorder heralds symptoms of Machado-Joseph disease years before ataxia. Mov Disord 2005;20:739-741.
34. Friedman JH, Fernandez HH, Sudarsky LR. REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3). Mov Disord 2003;18:1520-1522.
35. Schmahmann JD, Caplan D. Cognition, emotion and the cerebellum. Brain 2006;129:288-292.
36. Stoodley CJ, Schmahmann JD. Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing. Cortex 2010;46:831-844.
37. Radvany J, Camargo CHP, Costa ZM, Fonseca NC, Nascimento ED. Machado Joseph disease of Azorean ancestry in Brazil: the Catarina kindred. Neurological, neuroimaging, psychiatric and neuropsychological findings in the largest known family, the Catarina kindred. Arq Neuropsiquiatr 1993;51:21-30.
38. Zawacki TM, Grace J, Friedman JH, Sudarsky L. Executive and emotional dysfunction in Machado-Joseph disease. Mov Disord 2002;17:1004-1010.
39. Maruff P, Tyler P, Burt T, Currie B, Burns C, Currie J. Cognitive deficits in Machado-Joseph disease. Ann Neurol 1996;40:421-427.
40. Kawai Y, Takeda A, Abe Y, Washimi Y, Tanaka F, Sobue G. Cognitive impairments in Machado-Joseph disease. Arch Neurol 2004;61:1757-1760.
41. Braga-Neto P, Pedroso JL, Alessi H, et al. Cerebellar cognitive affective syndrome in Machado Joseph disease: core clinical features. Cerebellum 2011;11:549-556.
42. Manto M, Lorivel T. Cognitive repercussions of hereditary cerebellar disorders. Cortex 2011;47:81-110.
43. Braga-Neto P, Dutra LA, Pedroso JL, et al. Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas. Cerebellum 2012;11:1037-1044.
44. Schmitz-Hubsch T, Coudert M, Giunti P, et al. Self-rated health status in spinocerebellar ataxia-results from a European multicenter study. Mov Disord 2010;25:587-595.
45. Schmitz-Hubsch T, Coudert M, Tezenas du Montcel S, et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord 2011;26:870-876.
46. Cecchin CR, Pires AP, Rieder CR, et al. Depressive symptoms in Machado-Joseph disease (SCA3) patients and their relatives. Commun Genet 2007;10:19-26.
47. Saute JA, da Silva AC, Donis KC, Vedolin L, Saraiva-Pereira ML, Jardim LB. Depressive mood is associated with ataxic and non-ataxic neurological dysfunction in SCA3 patients. Cerebellum 2010;9:603-605.
48. Rodrigues CS, de Oliveira VZ, Camargo G, et al. Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing. J Genet Couns 2012;21:101-112.
49. Wolf U, Rapoport MJ, Schweizer TA. Evaluating the affective component of the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci 2009;21:245-253.
50. Monte TL, Rieder CR, Tort AB, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003;107:207-210.
51. Silva RC, Saute JA, Silva AC, Coutinho AC, Saraiva-Pereira ML, Jardim LB. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J Med Biol Res 2010;43:537-542.
52. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003;18:364-372.
53. Fernandez-Ruiz J, Diaz R, Hall-Haro C, et al. Olfactory dysfunction in hereditary ataxia and basal ganglia disorders. Neuroreport 2003;14:1339-1341.
54. Connelly T, Farmer JM, Lynch DR, Doty RL. Olfactory dysfunction in degenerative ataxias. J Neurol Neurosurg Psychiatr 2003;74:1435-1437.
55. Abele M, Riet A, Hummel T, Klockgether T, Wullner U. Olfactory dysfunction in cerebellar ataxia and multiple system atrophy. J Neurol 2003;250:1453-1455.
56. Velazquez-Perez L, Fernandez-Ruiz J, Diaz R, et al. Spinocerebellar ataxia type 2 olfactory impairment shows a pattern similar to other major neurodegenerative diseases. J Neurol 2006;253:1165-1169.
57. Braga-Neto P, Felicio AC, Pedroso JL, et al. Clinical correlates of olfactory dysfunction in spinocerebellar ataxia type 3. Parkinsonism Relat Disord 2011;17:353-356.
58. Moscovich M, Munhoz RP, Teive HA, et al. Olfactory impairment in familial ataxias. J Neurol Neurosurg Psychiatry 2012;83:970-974.
59. Kim YT, Shin SM, Lee WY, Kim GM, Jin DK. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila). Cell Mol Neurobiol 2004;24:109-122.
60. Sobel N, Prabhakaran V, Hartley CA, et al. Odorant-induced and sniff-induced activation in the cerebellum of the human. J Neurosci 1998;18:8990-9001.
61. Coutinho P, Guimaraes A, Pires MM, Scaravilli F. The peripheral neuropathy in Machado-Joseph disease. Acta Neuropathol (Berl) 1986;71:119-124.
62. Kinoshita A, Hayashi M, Oda M, Tanabe H. Clinicopathological study of the peripheral nervous system in Machado-Joseph disease. J Neurol Sci 1995;130:48-58.
63. van de Warrenburg BPC, Notermans NC, Schelhaas HJ, et al. Peripheral nerve involvement in spinocerebellar ataxias. Arch Neurol 2004;61:257-261.
64. Franca MC Jr, D'Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Prospective study of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve 2009;40:1012-1018.
65. Klockgether T, Schols L, Abele M, et al. Age related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). J Neurol Neurosurg Psychiatry 1999;66:222-224.
66. Friedman JH, Amick MM. Fatigue and daytime somnolence in Machado-Joseph disease (spinocerebellar ataxia type 3). Mov Disord 2008;23:1323-1324.
67. Franca MC Jr, D'Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability abnormalities in Machado-Joseph disease. Arch Neurol 2008;65:525-529.
68. Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003;126:965-973.
69. Franca MC Jr, D'Abreu A, Friedman JH, Nucci A, Lopes-Cendes I. Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. Arch Neurol 2007;64:1767-1770.
70. Yeh TH, Lu CS, Chou YH, et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol 2005;62:630-636.
71. Franca MC Jr, D'Abreu A, Nucci A, Lopes-Cendes I. Clinical correlates of autonomic dysfunction in patients with Machado-Joseph disease. Acta Neurol Scand 2010;121:422-425.
72. Pradhan C, Yashavantha BS, Pal PK, Sathyaprabha TN. Spinocerebellar ataxias type 1, 2 and 3: a study of heart rate variability. Acta Neurol Scand 2008;117:337-342.
73. Yamanaka Y, Asahina M, Akaogi Y, et al. Cutaneous sympathetic dysfunction in patients with Machado-Joseph disease. Cerebellum 2012;11:1057-1060.
74. Asahina M, Katagiri A, Yamanaka Y, et al. Spectral analysis of heart rate variability in patients with Machado-Joseph disease. Auton Neurosci 2010;154:99-101.
75. Kazuta T, Hayashi M, Shimizu T, Iwasaki A, Nakamura S, Hirai S. Autonomic dysfunction in Machado-Joseph disease assessed by iodine123-labeled metaiodobenzylguanidine myocardial scintigraphy. Clin Auton Res 2000;10:111-115.
76. Takiyama Y, Sakoe K, Nakano I, Nishizawa M. Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology 1997;49:604-606.
77. van Gaalen J, Giunti P, van de Warremburg BP. Movement disorders in spinocerebellar ataxias. Mov Disord 2011;26:792-800.
78. Schols L, Peters S, Szymanski S, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57:1495-1500.
79. Schimitz-Hubsch T, Coundert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, and 6. Disease severity and nonataxia symptoms. Neurology 2008;71:982-989.
80. Tuite PJ, Rogaeva EA, St George-Hyslop PH, Lang AE. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995;38:684-687.
81. Bettencourt C, Santos C, Coutinho P, et al. Parkinsonism phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report [serial online]. BMC Neurol 2011;11:131.
82. Socal MP, Emmel VE, Rieder CR, Hilbig A, Saraiva-Pereira ML, Jardim LB. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat Disord 2009;15:374-378.
83. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch Neurol 2001;58:296-299.
84. Subramony SH, Hernandez D, Adam A, et al. Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. Mov Disord 2002;17:1068-1071.
85. Lu CS, Chang HC, Kuo PC, et al. The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. Parkinsonism Relat Disord 2004;10:369-373.
86. Teive HAG, Munhoz RP, Arruda WO, et al. Spinocerebellar ataxias-Genotype-phenotype correlation in 104 Brazilian families. Clinics (Sao Paulo) 2012;67:443-449.
87. Pedroso JL, Bor-Seng-Shu E, Braga-Neto P, Teixeira MJ, Barsottini OG. Transcranial sonography: Brazilian experience. Arq Neuropsiquiatr 2012;70:313-314.
88. Siebert M, Donis KC, Socal M, et al. Glucocerebrosidase gene variants in parkinsonism patients with Machado-Joseph/spinocerebellara ataxia 3. Parkinsonism Relat Disord 2012;18:185-190.
89. Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorean Portuguese family. Neurology 1980;30:319-322.
90. Cardoso F, de Oliveira JT, Puccioni-Sohler M, Fernandes AR, de Mattos JP, Lopes-Cendes I. Eyelid dystonia in Machado-Joseph disease. Mov Disord 2000;15:1028-1030.
91. Pedroso JL, Braga-Neto P, Felicio AC, Barsottini OG, Jardim LB, Saraiva-Pereira ML. Akathisia: an unusual movement disorder in Machado-Joseph disease. Parkinsonism Relat Disord 2011;17:12-13.
92. Pedroso JL, Felicio AC, Braga-Neto P, Barsottini OG. Movement disorders in spinocerebellar ataxias [letter]. Mov Disord 2011;26:2302.
93. Freeman W, Wszolek Z. Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease) [letter]. Mov Disord 2005;20:644.
94. Saute JA, da Silva AC, Souza GN, et al. Body mass index is inversely correlated with the expanded CAG repeat length in SCA3/MJD patients. Cerebellum 2012;11:771-774.
95. Saute JA, da Silva AC, Muller AP, et al. Serum insulin-like system alterations in patients with spinocerebellar ataxia type 3. Mov Disord 2011;26:731-735.
96. Boy J, Schmidt T, Wolburg H, et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet 2009;18:4282-4295.